Satori Capital announced the launch of Satori Neuro, a new strategy targeting transformational companies developing breakthrough treatments and disruptive business models to address the world’s most critical mental health challenges. Supporting this kind of innovation aligns directly with Satori’s purpose: To create, fund, and inspire businesses that elevate humanity.
Satori Neuro is led by chief investment officer Dr. Amy Kruse, who has more than 20 years of experience in science, technology, and innovation, with a special focus on neurotechnology and human performance.
“Amy’s experience and subject matter expertise, as well as her impressive professional background, position her ideally to lead this innovative neuroscience and mental-health-related strategy,” said Satori co-founder and managing partner Randy Eisenman. “Along with our principals’ operating experience in building and managing successful companies, we believe Amy’s unique expertise, experience, and relationships give us a distinct advantage in recognizing the most promising and innovative businesses in the sector.”
Under Dr. Kruse’s direction, Satori Neuro will seek out opportunities to address the largest mental health, brain health, and wellness challenges and opportunities. The innovative therapeutics involved include a wide range of treatment approaches, from psychedelic medicine and transcranial magnetic stimulation to virtual/augmented reality protocols and non-invasive brainwave devices, all designed to provide solutions for challenges such as treatment-resistant depression, post-traumatic stress disorder, addiction and substance abuse, neurological disorders, and more.
This communication is for informational purposes and is not intended to be, nor should it be construed or used as an offer to sell, or a solicitation of any offer to buy shares or limited partnership interests in any funds managed by Satori Capital.